Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy
dc.contributor.author | Woods Ignatoski, Kathleen M. | en_US |
dc.contributor.author | Friedman, Judah | en_US |
dc.contributor.author | Escara-Wilke, June | en_US |
dc.contributor.author | Zhang, Xiaohua | en_US |
dc.contributor.author | Daignault, Stephanie D. | en_US |
dc.contributor.author | Dunn, Rodney L. | en_US |
dc.contributor.author | Smith, David C. | en_US |
dc.contributor.author | Keller, Evan T. | en_US |
dc.date.accessioned | 2010-10-14T14:20:06Z | |
dc.date.available | 2010-10-14T14:20:06Z | |
dc.date.issued | 2009-02 | en_US |
dc.identifier.citation | Woods Ignatoski, Kathleen M.; Friedman, Judah; Escara-Wilke, June; Zhang, Xiaohua; Daignault, Stephanie; Dunn, Rodney L.; Smith, David C.; Keller, Evan T. (2008/11/17). "Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy." Journal of Interferon & Cytokine Research, 29(2): 105-112 <http://hdl.handle.net/2027.42/78145> | en_US |
dc.identifier.issn | 1079-9907 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78145 | |
dc.description.abstract | Men with androgen-independent prostate cancer (AIPC) frequently have bone metastasis. The effects of chemotherapy on markers of bone metabolism have not been well characterized. We conducted a prospective study of patients with AIPC randomized in the first cycle to receive either docetaxel/estramustine or zoledronic acid, a bisphosphonate, to inhibit osteoclastic activity. Here we report the effects of therapy on markers of bone metabolism in these patients following the first cycle of therapy. Serum levels of several indices of bone remodeling were evaluated using commercial enzyme-linked immunosorbent assays. Changes in markers of bone metabolism were compared in patients receiving initial chemotherapy versus bisphosphonate. There was no significant difference in median change in any of the measured bone markers in patients given zoledronic acid when compared to chemotherapy. When comparing responders to nonresponders, overall interleukin-6 (IL-6) decreased by 35% in prostate-specific antigen responders; whereas, IL-6 levels increased by 76% in nonresponders (p = 0.03). Elevated IL-6 levels and reductions in IL-6 levels early in treatment may reflect ultimate clinical response to docetaxel-based regimens. | en_US |
dc.format.extent | 224553 bytes | |
dc.format.extent | 3100 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Mary Ann Liebert, Inc. | en_US |
dc.title | Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy | en_US |
dc.type | Article | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 19014338 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78145/1/jir.2008.0024.pdf | |
dc.identifier.doi | 10.1089/jir.2008.0024 | en_US |
dc.identifier.source | Journal of Interferon & Cytokine Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.